Some commentary from Macquarie emailed yesterday, this looks to be a major issue ATM and keeping the share price well below the 4.77 high.
Emerging Leaders Acrux ACR Underperform Rebates remain stubbornly high
* Eli Lilly reported Axiron 4Q net sales at US$23.9m (vs. Macq at US$22.6m). * Solid net sales number due to lower than expected rebate; however, it appears that the rebate has increased on a seasonally adjusted basis. * Underperform. Positive that Q4 rebates were lower than Q3, but still increased on a seasonally adjusted basis and concern about slowing market growth.
ACR Price at posting:
$3.45 Sentiment: LT Buy Disclosure: Held
